GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Channel Therapeutics Corp (AMEX:CHRO) » Definitions » Total Debt per Share

CHRO (Channel Therapeutics) Total Debt per Share : $0.39 (As of Sep. 2024)


View and export this data going back to 2024. Start your Free Trial

What is Channel Therapeutics Total Debt per Share?

$0.39 (As of Sep. 2024)

Total Debt per Share is calculated as total debt divided by Shares Outstanding (EOP). Total debt is calculated as Long-Term Debt & Capital Lease Obligation plus Short-Term Debt & Capital Lease Obligation. Channel Therapeutics's Total Debt Per Share for the quarter that ended in Sep. 2024 was $0.39.


Channel Therapeutics Total Debt per Share Historical Data

The historical data trend for Channel Therapeutics's Total Debt per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Channel Therapeutics Total Debt per Share Chart

Channel Therapeutics Annual Data
Trend Dec20 Dec21 Dec22 Dec23
Total Debt per Share
0.03 - 0.06 0.22

Channel Therapeutics Quarterly Data
Dec20 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Total Debt per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.21 0.22 - 0.27 0.39

Channel Therapeutics Total Debt per Share Calculation

Channel Therapeutics's Total Debt Per Share for the fiscal year that ended in Dec. 2023 is calculated as:

Channel Therapeutics's Total Debt Per Share for the quarter that ended in Sep. 2024 is calculated as:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Channel Therapeutics Total Debt per Share Related Terms

Thank you for viewing the detailed overview of Channel Therapeutics's Total Debt per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Channel Therapeutics Business Description

Comparable Companies
Traded in Other Exchanges
N/A
Address
4400 Route 9 South, Suite 1000, Freehold, NJ, USA, 07728
Channel Therapeutics Corp is a clinical-stage biotechnology company developing and commercializing novel, non-opioid, non-addictive therapeutics to alleviate pain. The initial clinical focus is to selectively target the sodium ion channel known as NaV1.7 for the treatment of various types of chronic pain, acute and chronic eye pain, and post-surgical nerve blocks. Its pipeline includes CC8464 for ISFN and EM and CT2000 for Acute and CHronic Eye Pain-Dry Eye Disease.

Channel Therapeutics Headlines

From GuruFocus

Chromocell Announces Stock Repurchase Plan

By Marketwired 08-07-2024